Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

381 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902.
Kanazawa K, Yokouchi H, Wang X, Ishida T, Fujita Y, Fujiuchi S, Harada T, Harada M, Takamura K, Oizumi S, Kinoshita I, Katsuura Y, Honjo O, Kojima T, Dosaka-Akita H, Isobe H, Munakata M, Nishimura M; Hokkaido Lung Cancer Clinical Study Group. Kanazawa K, et al. Among authors: takamura k. Cancer Chemother Pharmacol. 2014 Dec;74(6):1149-57. doi: 10.1007/s00280-014-2589-3. Epub 2014 Oct 8. Cancer Chemother Pharmacol. 2014. PMID: 25294632 Clinical Trial.
Elevated serum KL-6 concentrations in patients with diabetes mellitus.
Takahashi T, Takamura K, Sakaue S, Ishii J, Yokouchi H, Nasuhara Y. Takahashi T, et al. Among authors: takamura k. J Diabetes Complications. 2002 Sep-Oct;16(5):352-8. doi: 10.1016/s1056-8727(01)00220-3. J Diabetes Complications. 2002. PMID: 12200080
A phase II study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901.
Harada T, Oizumi S, Ito K, Takamura K, Kikuchi E, Kuda T, Sugawara S, Suzuki A, Maemondo M, Fujita Y, Kinoshita I, Inoue A, Hommura F, Katsuura Y, Dosaka-Akita H, Isobe H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group. Harada T, et al. Among authors: takamura k. Oncologist. 2013;18(4):439-45. doi: 10.1634/theoncologist.2012-0308. Epub 2013 Feb 26. Oncologist. 2013. PMID: 23442308 Free PMC article. Clinical Trial.
A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
Matsumoto Y, Maemondo M, Ishii Y, Okudera K, Demura Y, Takamura K, Kobayashi K, Morikawa N, Gemma A, Ishimoto O, Usui K, Harada M, Miura S, Fujita Y, Sato I, Saijo Y; North-East Japan Study Group. Matsumoto Y, et al. Among authors: takamura k. Lung Cancer. 2014 Nov;86(2):195-200. doi: 10.1016/j.lungcan.2014.08.019. Epub 2014 Sep 16. Lung Cancer. 2014. PMID: 25249428 Clinical Trial.
Prognostic impact of clinical variables on surgically resected small-cell lung cancer: Results of a retrospective multicenter analysis (FIGHT002A and HOT1301A).
Yokouchi H, Ishida T, Yamazaki S, Kikuchi H, Oizumi S, Uramoto H, Tanaka F, Harada M, Akie K, Sugaya F, Fujita Y, Fukuhara T, Takamura K, Kojima T, Harada T, Higuchi M, Matsuura Y, Honjo O, Minami Y, Watanabe N, Nishihara H, Suzuki H, Dosaka-Akita H, Isobe H, Nishimura M, Munakata M. Yokouchi H, et al. Among authors: takamura k. Lung Cancer. 2015 Dec;90(3):548-53. doi: 10.1016/j.lungcan.2015.10.010. Epub 2015 Oct 14. Lung Cancer. 2015. PMID: 26604032
Immunohistochemical profiling of receptor tyrosine kinases, MED12, and TGF-βRII of surgically resected small cell lung cancer, and the potential of c-kit as a prognostic marker.
Yokouchi H, Nishihara H, Harada T, Ishida T, Yamazaki S, Kikuchi H, Oizumi S, Uramoto H, Tanaka F, Harada M, Akie K, Sugaya F, Fujita Y, Takamura K, Kojima T, Higuchi M, Honjo O, Minami Y, Watanabe N, Goto A, Suzuki H, Dosaka-Akita H, Isobe H, Nishimura M, Munakata M. Yokouchi H, et al. Among authors: takamura k. Oncotarget. 2017 Jun 13;8(24):39711-39726. doi: 10.18632/oncotarget.14410. Oncotarget. 2017. PMID: 28055980 Free PMC article.
Expression of Notch1 and Numb in small cell lung cancer.
Kikuchi H, Sakakibara-Konishi J, Furuta M, Yokouchi H, Nishihara H, Yamazaki S, Uramoto H, Tanaka F, Harada M, Akie K, Sugaya F, Fujita Y, Takamura K, Kojima T, Harada T, Higuchi M, Honjo O, Minami Y, Watanabe N, Oizumi S, Suzuki H, Ishida T, Dosaka-Akita H, Isobe H, Munakata M, Nishimura M. Kikuchi H, et al. Among authors: takamura k. Oncotarget. 2017 Feb 7;8(6):10348-10358. doi: 10.18632/oncotarget.14411. Oncotarget. 2017. PMID: 28060745 Free PMC article.
A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002).
Ikezawa Y, Asahina H, Oizumi S, Watanabe M, Takamura K, Kawai Y, Yamada N, Harada T, Kinoshita I, Fujita Y, Miyauchi E, Ogi T, Amano T, Furuta M, Sakakibara-Konishi J, Nishihara H, Dosaka-Akita H, Isobe H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group. Ikezawa Y, et al. Among authors: takamura k. Cancer Chemother Pharmacol. 2017 Nov;80(5):955-963. doi: 10.1007/s00280-017-3432-4. Epub 2017 Sep 13. Cancer Chemother Pharmacol. 2017. PMID: 28905108 Free article. Clinical Trial.
Rikkunshito for Preventing Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: Results from 2 Prospective, Randomized Phase 2 Trials.
Harada T, Amano T, Ikari T, Takamura K, Ogi T, Fujikane T, Fujita Y, Taima K, Tanaka H, Sasaki T, Okumura S, Sugawara S, Yokouchi H, Yamada N, Morikawa N, Dosaka-Akita H, Isobe H, Nishimura M. Harada T, et al. Among authors: takamura k. Front Pharmacol. 2018 Jan 16;8:972. doi: 10.3389/fphar.2017.00972. eCollection 2017. Front Pharmacol. 2018. PMID: 29387008 Free PMC article.
381 results